Cornell spinout Lexeo Therapeutics has added $100m to its coffers thanks to a series B round co-led by D1 Capital Partners and Eventide Asset Management.

Lexeo Therapeutics, a US-based gene therapy developer spun out of Cornell University, has raised $100m in a series B round co-led by asset managers D1 Capital Partners and Eventide Asset Management.
The round included life sciences real estate investment trust Alexandria Real Estate Equities’ investment arm Alexandria Venture Investments and Lundbeckfonden Ventures, an evergreen fund for Lundbeckfonden, the foundation that owns pharmaceutical firm Lundbeck.
Verition Fund Management, Laurion Capital Management, Longitude Capital, Gray’s Creek Capital, Omega Funds, Janus…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
email
Linked in